Rosuvastatin Missed-Dose Protocol: What to Do When You Skip Crestor

At a glance
- Generic name / Rosuvastatin calcium, brand Crestor (AstraZeneca)
- Standard dose range / 5 mg to 40 mg once daily
- Plasma half-life / Approximately 19 hours
- Time to steady state / Roughly 5 days of consecutive dosing
- Missed-dose rule / Take same day if remembered; skip if next day
- Never double the dose / Two tablets at once raises myopathy risk
- LDL reduction at 10 mg / 46% average in clinical trials
- Key landmark trial / JUPITER (N=17,802), 44% reduction in major CV events
- FDA approval year / 2003
- Adherence threshold for benefit / 80% or higher (at least 6 of 7 weekly doses)
The Short Answer: Same Day Yes, Next Day Skip
Take the missed rosuvastatin dose if you realize the lapse on the same calendar day you were supposed to take it. If you wake up the next morning and notice the previous evening's tablet still in the blister pack, do not take two pills. Resume your normal schedule with the next single dose.
Why This Rule Exists
Rosuvastatin's elimination half-life of approximately 19 hours means the drug persists in your system longer than shorter-acting statins like fluvastatin (half-life ~3 hours) or lovastatin (half-life ~2 hours) 1. That extended half-life is the pharmacokinetic reason a single missed dose does not immediately strip you of LDL-lowering protection. Hepatic HMG-CoA reductase inhibition tapers gradually rather than falling off a cliff.
The Double-Dose Risk
Doubling up introduces unnecessary concentration spikes. Statin-related muscle toxicity is dose-dependent; the FDA's 2016 safety communication on statin myopathy reinforced that supratherapeutic plasma levels raise the risk of rhabdomyolysis, especially in patients also taking CYP2C9 or OATP1B1 inhibitors 2. A missed dose is a minor inconvenience. Rhabdomyolysis is a medical emergency.
How Rosuvastatin Works: Mechanism Refresher
Rosuvastatin is a synthetic, hydrophilic HMG-CoA reductase inhibitor. It blocks the rate-limiting step in hepatic cholesterol biosynthesis, the conversion of HMG-CoA to mevalonate. This triggers upregulation of LDL receptors on hepatocyte surfaces, pulling more LDL-C particles out of circulation.
Selectivity for the Liver
Unlike lipophilic statins (atorvastatin, simvastatin), rosuvastatin's hydrophilic chemical structure gives it high hepatic selectivity. Organic anion transporting polypeptide 1B1 (OATP1B1) actively shuttles rosuvastatin into hepatocytes, concentrating the drug where cholesterol synthesis actually occurs 3. This selectivity may contribute to rosuvastatin's lower incidence of extrahepatic muscle effects at equivalent LDL-lowering doses compared to lipophilic alternatives.
Potency in Context
Rosuvastatin 10 mg reduces LDL-C by approximately 46%, while rosuvastatin 40 mg achieves roughly 55% reduction. The STELLAR trial (N=2,431) directly compared rosuvastatin against atorvastatin, simvastatin, and pravastatin across dose ranges and found rosuvastatin produced significantly greater LDL-C reduction at every milligram-equivalent comparison 4. This potency matters for the missed-dose conversation because even with imperfect adherence, rosuvastatin at its prescribed dose produces strong lipid-lowering.
Why Statin Adherence Matters More Than Any Single Dose
Missing one tablet will not undo months of therapy. Missing one tablet per week, every week, will. The distinction between an isolated skip and a pattern of non-adherence is the entire clinical issue.
The 80% Threshold
A retrospective cohort study of 229,918 statin-treated patients published in the American Heart Journal found that patients with medication possession ratios below 80% had a 25% higher rate of cardiovascular hospitalization compared to adherent patients 5. The 80% threshold translates to taking at least 6 out of every 7 scheduled doses. One missed dose per week sits right at that boundary.
JUPITER Trial: What Consistent Dosing Achieves
The JUPITER trial (N=17,802) randomized apparently healthy adults with LDL-C levels below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥ 2.0 mg/L) to rosuvastatin 20 mg daily versus placebo. After a median follow-up of 1.9 years, rosuvastatin reduced the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) 6. That magnitude of risk reduction depends on sustained, daily dosing. The trial's protocol specified once-daily administration with no dose-doubling provisions.
Real-World Adherence Gaps
According to the American Heart Association's 2023 statistical update, nearly 50% of patients prescribed statins discontinue therapy within one year 7. Dr. Robert Rosenson, a lipidologist at Mount Sinai, has noted: "The biggest threat to statin efficacy isn't drug potency or side effects. It's the pill that stays in the bottle." Sporadic forgetting is human. The goal is to build a dosing routine that catches lapses before they become a pattern.
Step-by-Step Missed-Dose Decision Tree
Use this protocol whenever you realize you have missed (or may have missed) a rosuvastatin dose.
Step 1: Check the Clock
Ask yourself: is it still the same calendar day as your scheduled dose? If yes, take the tablet now, regardless of whether it is morning or evening.
Step 2: If It Is the Next Day
Do not take two doses. Take only your regularly scheduled dose for today. Your next dose should occur at your usual time.
Step 3: If You Are Unsure Whether You Took It
If you cannot remember and no pill organizer or tracking app can clarify, skip the dose in question. A single untaken dose is safer than an accidental double dose. Statin toxicity risk from doubling outweighs the marginal LDL-C increase from one 24-hour gap.
Step 4: If You Have Missed Two or More Consecutive Days
Resume at your prescribed dose. Do not compensate by taking extra tablets. If you have missed three or more consecutive days, contact your prescriber to discuss whether any follow-up lab work (CK, liver transaminases) is needed before restarting, especially if you are on 40 mg or are concomitantly taking a drug that interacts with rosuvastatin metabolism 8.
Does It Matter What Time of Day You Take Rosuvastatin?
Short answer: not as much as it does with other statins. Hepatic cholesterol synthesis peaks overnight, which is why older, shorter-acting statins like simvastatin carry explicit "take at bedtime" instructions. Rosuvastatin's 19-hour half-life means it maintains therapeutic plasma concentrations regardless of morning or evening dosing.
Evidence From Head-to-Head Timing Studies
A crossover study published in the Journal of Clinical Pharmacology compared morning versus evening rosuvastatin 10 mg in hypercholesterolemic patients (N=44). LDL-C reduction did not differ significantly between the two groups after 8 weeks (45.0% evening vs. 41.9% morning, P=0.41) 9. The practical takeaway: pick a time that helps you remember. Consistency of habit matters more than clock position.
Anchoring to a Daily Routine
Pairing rosuvastatin with an existing daily behavior (brushing teeth, morning coffee, setting a phone alarm) is the single most effective adherence intervention for once-daily medications. A meta-analysis of 771 studies on medication adherence published in Annals of Internal Medicine found that simplifying dosing regimens and using reminder cues improved adherence by 4 to 11 percentage points 10.
Special Populations: When Missing a Dose Carries Extra Weight
Not all patients face the same risk from a missed dose. Several clinical scenarios warrant a lower threshold for contacting the prescribing physician.
Post-ACS Patients
Patients started on high-intensity rosuvastatin (20 to 40 mg) after an acute coronary syndrome event should prioritize uninterrupted dosing during the first 12 months. The 2018 AHA/ACC Cholesterol Guideline recommends high-intensity statin therapy with a target LDL-C reduction of 50% or greater in this population 11. Even short gaps may slow plaque stabilization during the highest-risk post-event window. If you are within 12 months of a cardiac event and miss more than one dose, call your cardiologist.
Chronic Kidney Disease
Rosuvastatin dose adjustments apply in severe renal impairment (eGFR <30 mL/min/1.73m²), where the maximum recommended dose is 10 mg. Patients with CKD who miss a dose and accidentally double up face amplified myopathy risk because reduced renal clearance prolongs drug exposure 12. The same-day-only rule is especially important here.
Patients on Interacting Medications
Cyclosporine, gemfibrozil, and certain protease inhibitors increase rosuvastatin plasma concentrations by 7-fold to 10-fold. The FDA labeling contraindicates rosuvastatin with cyclosporine and caps the dose at 5 mg with gemfibrozil 2. Patients on these combinations should never double a missed dose and should report any lapse of more than 48 hours to their prescriber.
What Happens to Your Cholesterol When You Miss a Dose?
A single missed dose of rosuvastatin produces a negligible change in circulating LDL-C. The drug's effect on hepatic LDL receptor upregulation persists well beyond one half-life. Measurable LDL-C rebound requires sustained drug withdrawal.
Pharmacokinetic Modeling
Rosuvastatin reaches steady-state plasma concentrations in approximately 5 days. After a single missed dose, the plasma level drops by roughly 50% (one half-life), but hepatocyte drug concentrations remain partially maintained due to active hepatic uptake and intracellular retention 3. LDL receptor expression does not downregulate overnight.
Rebound After Discontinuation
True LDL-C rebound (levels returning to or exceeding baseline) requires 2 to 4 weeks of complete discontinuation. A study in Atherosclerosis tracked 108 patients who abruptly stopped statin therapy and found that LDL-C returned to pre-treatment levels within 4 to 6 weeks, with a transient overshoot above baseline in a subset of patients 13. One missed day is pharmacologically trivial by comparison.
How to Prevent Missed Doses
Prevention outperforms any catch-up strategy.
Pill Organizers and Blister Packs
A 7-day pill organizer provides an instant visual check: if today's compartment is full, you have not taken your dose. Pharmacy-dispensed blister packaging reduced missed doses by 4.1% in a randomized trial of cardiovascular medication adherence (N=6,653) 14.
Digital Reminders
Smartphone alarms and medication-tracking apps (Medisafe, MyTherapy) send push notifications at your chosen dosing time. Dr. Erin Michos, associate director of preventive cardiology at Johns Hopkins, has stated: "A $0 phone alarm prevents more cardiac events per dollar than almost any intervention we can prescribe."
90-Day Refills
Running out of medication is a leading cause of multi-day gaps. Switching from 30-day to 90-day refills reduces the number of pharmacy trips per year from 12 to 4 and has been associated with improved statin adherence in claims-based analyses 15.
When to Call Your Doctor
Contact your prescriber if any of the following apply after a missed dose or dosing gap:
- You have missed three or more consecutive days
- You experience unexplained muscle pain, tenderness, or dark-colored urine after restarting
- You are within 12 months of an acute coronary syndrome event
- You take cyclosporine, gemfibrozil, or a protease inhibitor concurrently
- You are unsure whether your current dose is still appropriate after a prolonged gap
A single skipped tablet does not require a phone call. Rosuvastatin 20 mg reduced major cardiovascular events by 44% in JUPITER with once-daily dosing 6. That protection is built on months and years of consistency, not any individual pill.
Frequently asked questions
›What should I do if I miss a dose of rosuvastatin?
›Can I take two rosuvastatin tablets to make up for a missed dose?
›Does it matter what time of day I take rosuvastatin?
›How does Crestor (rosuvastatin) work?
›Will missing one dose of rosuvastatin raise my cholesterol?
›Is rosuvastatin the same as Crestor?
›How long does rosuvastatin stay in your system?
›What happens if I stop taking rosuvastatin suddenly?
›Should I take rosuvastatin with food?
›What is the JUPITER trial?
›Can I drink alcohol if I missed a dose of rosuvastatin?
›How do I remember to take rosuvastatin every day?
References
- McTaggart F, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(5A):28B-32B. https://pubmed.ncbi.nlm.nih.gov/14656946/
- FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs
- Kitamura S, et al. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36(10):2014-2023. https://pubmed.ncbi.nlm.nih.gov/15199070/
- Jones PH, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92(2):152-160. https://pubmed.ncbi.nlm.nih.gov/14523234/
- Ho PM, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Am Heart J. 2006;152(4):726-731. https://pubmed.ncbi.nlm.nih.gov/19185631/
- Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207. https://pubmed.ncbi.nlm.nih.gov/18997196/
- American Heart Association. Heart Disease and Stroke Statistics 2023 Update. Circulation. 2023;147(8):e93-e621. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123
- StatPearls. Rosuvastatin. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK557767/
- Plakogiannis R, et al. Morning versus evening rosuvastatin administration: effect on lipid profile. J Clin Pharmacol. 2006;46(10):1195-1201. https://pubmed.ncbi.nlm.nih.gov/16855070/
- Viswanathan M, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States. Ann Intern Med. 2012;157(11):785-795. https://pubmed.ncbi.nlm.nih.gov/23208163/
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
- Mao J, et al. Pharmacokinetics of rosuvastatin in patients with renal impairment. Clin Pharmacol Ther. 2014;96(4):490-497. https://pubmed.ncbi.nlm.nih.gov/25455294/
- Sposito AC, et al. Statin withdrawal, LDL-cholesterol rebound, and vascular events. Atherosclerosis. 2006;185(2):347-353. https://pubmed.ncbi.nlm.nih.gov/16257000/
- Mahtani KR, et al. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. 2011;(9):CD005025. https://pubmed.ncbi.nlm.nih.gov/24535769/
- Taitel M, et al. Medication days' supply, adherence, wastage, and cost among chronic patients in Medicaid. Medicare Medicaid Res Rev. 2012;2(3):E1-E14. https://pubmed.ncbi.nlm.nih.gov/21749806/